Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis

Pancreatic Cancer Clinical Trial

Official title:

A Phase 1b/2, Randomized, Controlled, Open-Label Study Evaluating the Safety and Efficacy of ABBV-927 Administered in Combination With Modified FOLFIRINOX (mFFX) With or Without Budigalimab Compared to mFFX in Subjects With Untreated Metastatic Pancreatic Adenocarcinoma

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04807972
• Other study ID #: M20-732
• Secondary ID: 2020-005767-31
• Status: Completed
• Phase: Phase 1/Phase 2
• Start date: May 28, 2021
• Est. completion date: March 25, 2024

Study information

• Verified date: May 2024
• Source: AbbVie
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Metastatic Pancreatic Cancer Disease is one of the most aggressive and deadliest forms of cancer with very poor survival. This study will evaluate adverse events and change in disease activity in participants 18 to 75 years of age with a body weight greater than or equal to 35 kg with Metastatic Pancreatic Cancer Disease treated with Intravenous (IV) infusion of modified FOLFIRINOX (mFFX) combined with IV infusions of ABBV-927 with or without Budigalimab.

ABBV-927 and Budigalimab are the investigational drugs being developed for treatment of Metastatic Pancreatic Cancer Disease. In this study, doctors will enroll participants between 18 and 75 years of age with a body weight greater than or equal to 35 kg diagnosed diagnosed with Metastatic Pancreatic Cancer Disease in 4 different groups, called treatment arms. Each group will receive different treatments. Approximately 129 adult participants will be enrolled in the study across approximately 27 sites worldwide.

Participants will receive ABBV-927 and Budigalimab as Intravenous (IV) Infusion in Phase 1b and Phase 2 on day 3 of every 28 day cycle, modified FOLFIRINOX as IV Infusion in Phase 1b and Phase 2 on Day1 and Day 15 of every 28 day cycle up to maximum of 2 years.

There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: March 25, 2024
• Est. primary completion date: March 25, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Body weight >= 35 kg.

• Histologically or cytologically confirmed diagnosis of pancreatic adenocarcinoma with metastatic disease.

• Measurable disease per Response Evaluation Criteria for Solid Tumors Version 1.1 (RECIST v1.1).

• Prior history of or clinically stable concurrent malignancy are eligible for enrollment provided the malignancy is clinically insignificant, no treatment is required, and the participant is clinically stable.

Exclusion Criteria:

• Participants with locally advanced disease.

• Participants with neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma.

• Prior radiotherapy, surgery, or systemic anti-cancer therapy for the treatment of metastatic pancreatic adenocarcinoma.

• Prior radiotherapy, surgery, or systemic anti-cancer therapy in the adjuvant setting, or earlier, within the last 4 months.

• Prior radiotherapy to any measurable metastatic lesion at any time.

• Clinically significant third-space fluid accumulation (e.g., ascites or pleural effusion).

• Known metastases to the central nervous system (CNS).

Related Conditions & MeSH terms

• Pancreatic Cancer
• Pancreatic Neoplasms

Intervention

Drug:
• ABBV-927
Intravenous (IV) Infusion
• Budiglimab
Intravenous (IV) Infusion
• modified FOLFIRINOX
Intravenous (IV) Infusion

Locations

Country	Name	City	State
Australia	Monash Medical Centre /ID# 231379	Clayton	Victoria
Australia	Austin Health /ID# 231378	Heidelberg	Victoria
Israel	Rambam Health Care Campus /ID# 229555	Haifa	H_efa
Israel	The Chaim Sheba Medical Center /ID# 226812	Ramat Gan	Tel-Aviv
Korea, Republic of	Asan Medical Center /ID# 230282	Seoul	Seoul Teugbyeolsi
Korea, Republic of	Yonsei University Health System Severance Hospital /ID# 230280	Seoul	Seoul Teugbyeolsi
Puerto Rico	Pan American Center for Oncology Trials, LLC /ID# 228210	Rio Piedras
Spain	Hospital Universitario Vall d'Hebron /ID# 230226	Barcelona
Spain	Hospital Universitario 12 de Octubre /ID# 230102	Madrid
Spain	Hospital Universitario Miguel Servet /ID# 230139	Zaragoza
United States	UCHSC Anschultz Cancer Pavilion /ID# 227841	Aurora	Colorado
United States	Johns Hopkins Hospital /ID# 226713	Baltimore	Maryland
United States	Cleveland Clinic Main Campus /ID# 231135	Cleveland	Ohio
United States	Univ Hosp Cleveland /ID# 226807	Cleveland	Ohio
United States	Penn State Hershey Medical Ctr /ID# 229837	Hershey	Pennsylvania

Sponsors (1)

Lead Sponsor	Collaborator
AbbVie

Countries where clinical trial is conducted

United States,  Australia,  Israel,  Korea, Republic of,  Puerto Rico,  Spain, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase 1b: Percentage of participants experiencing Adverse Events	An adverse event (AE) is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. The investigator assesses the relationship of each event to the use of study drug as either probably related, possibly related, probably not related or not related.	Up to 6 months
Primary	Phase 1b: Number of Participants with Potentially Clinically Significant (PCS) Laboratory (Hematological and Chemistry) Values	Baseline values and changes from baseline will be summarized for each scheduled post-baseline visit for laboratory data as applicable. If more than one measurement exists for a participant on a particular day and time, an arithmetic average will be calculated. This average will be that participant's measurement for that day. For participants that do not have any post-baseline measurements, only their baseline values will be summarized.	Up to 6 months
Primary	Phase 1b: Number of Participants with Potentially Clinically Significant (PCS) Vital Signs	Baseline values and changes from baseline will be summarized for each scheduled post-baseline visit for vital signs data.	Up to 6 months
Primary	Phase 1b: Number of Participants with Dose Limiting Toxicities (DLT)	A DLT is defined as any serious AE for which a clear alternative cause cannot be established (e.g., attributed to the disease under study, another disease, or to a concomitant medication [e.g., COVID-19 vaccine] by the investigator or AbbVie Therapeutic Area (TA) MD] that occurs during the DLT observation period, and is not listed as a predefined exception in the protocol.	Up to 6 months
Primary	Phase 2: Overall Survival	Overall survival is defined as the time between the date of randomization and death due to any cause.	48 months.
Secondary	Phase 1b and Phase 2: Maximum Plasma Concentration (Cmax)	The maximum plasma concentration (Cmax; measured in ng/mL) is the highest concentration that a drug achieves in the blood after administration in a dosing interval.	Up to approximately 3 months
Secondary	Phase 1b and Phase 2: Time to Maximum Observed Plasma Concentration (Tmax)	The time to maximum plasma concentration (Tmax; measured in hours) is the time it takes for a drug to achieve Cmax.	Up to approximately 3 months
Secondary	Phase 1b and Phase 2: Area Under the Concentration-time Curve Over the Time Interval (AUC) in Plasma	The area under the plasma concentration-time curve (AUC; measured in ng*hr/mL) is a method of measurement of the total exposure of a drug in blood plasma.	Up to approximately 3 months.
Secondary	Phase 1b and Phase 2: Objective Response Rate (ORR)	ORR is defined as the percentage of participants whose best overall response is either complete response (CR) or partial response (PR) per investigator assessment according to RECIST version 1.1.	Up to approximately 27 months
Secondary	Phase 1b and Phase 2: Clinical Benefit Rate (CBR)	Clinical Benefit Rate (CBR) is defined as the percentage of participants whose best overall response is either Complete Response (CR), Partial Response (PR), or stable disease (SD) according to RECIST version 1.1.	Up to approximately 27 months
Secondary	Phase 1b and Phase 2: Duration of Response (DOR) for Participants Who Achieve a Documented Confirmed Response of CR/PR	DOR is defined as the time from the initial response of CR/PR per investigator review according to RECIST version 1.1 criteria to the first occurrence of radiographic disease progression, clinical progression or death from any cause whichever occurs first.	Up to approximately 27 months
Secondary	Phase 1b and Phase 2: Progression Free Survival (PFS)	PFS is defined as the time from randomization to a documented radiographic disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, clinical progression or death from any cause, whichever occurs earlier.	Up to approximately 24 months after study drug discontinuation
Secondary	Phase 1b and Phase 2: Quality of Life(QoL)-Measure Participant Overall Perceptions of Their Change in Pancreatic Cancer Symptoms includes the Patient Global Impression of Severity (PGIS) and the the Patient Global Impression of Change (PGIC)	Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) will measure participants' overall perceptions of their pancreatic cancer symptoms over time.	Up to approximately 25 months
Secondary	Phase 2: Percentage of Participants Experiencing Adverse Events	An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.	Up to approximately 27 months.